Laborie Medical Technologies has entered into an agreement to acquire the JADA System from Organon for up to $465 million. The transaction includes $440 million paid at closing and a milestone payment of up to $25 million based on 2026 revenue targets.
The JADA System is an FDA-cleared device for rapid control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The device has launched in over 20 countries and is available in more than 2,000 hospitals across the United States.
The transaction is expected to close in the first quarter of 2026, subject to closing conditions and regulatory approvals.
“Childbirth is one of the most personal and profound moments in a woman’s life, and every mother deserves to feel supported throughout it,” said Chris Smith, President and CEO of Laborie. “The JADA System helps care teams provide treatment when it matters most and being part of that mission is something we hold with deep pride and purpose at Laborie.”
According to Organon, the JADA System has been used to help more than 136,000 mothers in over 20 countries.
“This transaction puts a med tech asset in the hands of Laborie, a leading medical technology innovator with an established history in maternal health well-positioned to further expand access to JADA for the benefit of mothers globally,” said Joseph Morrissey, interim Chief Executive Officer at Organon.
Laborie is a medical technology company focused on urology, urogynecology, gastroenterology, obstetrics, gynecology, and neonatal health. The company is headquartered in Portsmouth, New Hampshire, and is a portfolio company of Patricia Industries, part of Investor AB.
